A probabilistic model for analyzing viral risks of plasma-derived medicinal products

Transfusion

Volumn 48, Issue 1, 2008, Pages 153-162

  Janssen, Mart P ^a   Over, Jan ^a   Van Der Poel, Cees L ^a   Cuijpers, H Theo M ^a   Van Hout, Ben A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DERIVATIVE; BLOOD DERIVED MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

APHERESIS; ARTICLE; BLOOD; BLOOD DONOR; CALCULATION; DONATION INTERVAL; DONATION SIZE; DRUG MANUFACTURE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION RISK; LAW; MARKETING; MATHEMATICAL MODEL; MONTE CARLO METHOD; PARAMETER; PLASMA; POLICY; PROBABILITY; PROBABILITY MODEL; QUALITY CONTROL; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VIRAL CONTAMINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

BLOOD COMPONENT TRANSFUSION; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; RISK ASSESSMENT; VIRUS DISEASES;

EID: 37549000596     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01493.x     Document Type: Article

References (13)

1. EMEA. Guideline on assessing the risk for virus transmission - new chapter 6 of the note for guidance on plasma-derived medicinal products. CPMP/BWP/269/95, CPMP/BWP/5180/03. London : EMEA 2004.
2. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 72.
3. Glynn SA, Kleinman SH, Wright DJ, Busch MP NHLBI Retrovirus Epidemiology Donor Study. International application of the incidence rate/window period model. Transfusion 2002 42 : 966 72.
4. Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002 42 : 537 48.
5. EMEA. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95. London : EMEA 1996.
6. Terpstra FG, Parkkinen J, Tölö H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Törmä E, van Engelenburg FA. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006 90 : 21 32.
7. Farshid M. Viral safety evaluation of plasma-derived therapeutic products. Dev Biol (Basel) 2004 118 : 11 5.
8. Darling AJ. Considerations in performing virus spiking experiments and process validation studies. Dev Biol Stand 1993 81 : 221 9.
9. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006 46 : 956 65.
10. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
11. Jongerius JM, Sjerps M, Cuijpers HT, van Drimmelen HA, van der Poel CL, Reesink HW, Molijn MH, Peeters GA, Peeters TP, Lelie PN. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. Transfusion 2002 42 : 792 7.
12. Sanquin annual report 2003. Amsterdam : Sanquin Blood Supply Foundation 2004.
13. Kleinman SH, Busch MP. The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000 13 : 631 49.